217 related articles for article (PubMed ID: 33304784)
1. Precise delivery of obeticholic acid
Ji G; Ma L; Yao H; Ma S; Si X; Wang Y; Bao X; Ma L; Chen F; Ma C; Huang L; Fang X; Song W
Acta Pharm Sin B; 2020 Nov; 10(11):2171-2182. PubMed ID: 33304784
[TBL] [Abstract][Full Text] [Related]
2. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis.
Zhou J; Huang N; Guo Y; Cui S; Ge C; He Q; Pan X; Wang G; Wang H; Hao H
Acta Pharm Sin B; 2019 May; 9(3):526-536. PubMed ID: 31193776
[TBL] [Abstract][Full Text] [Related]
3. Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling.
Azizsoltani A; Hatami B; Zali MR; Mahdavi V; Baghaei K; Alizadeh E
Biomed Pharmacother; 2023 Dec; 168():115777. PubMed ID: 37913732
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
5. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway.
Gou H; Liu S; Liu L; Luo M; Qin S; He K; Yang X
Front Immunol; 2022; 13():1095915. PubMed ID: 36605219
[TBL] [Abstract][Full Text] [Related]
7. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
12. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic acid protects against lithocholic acid-induced exogenous cell apoptosis during cholestatic liver injury.
Lu Q; Zhu Y; Wang C; Zhang R; Miao Y; Chai Y; Jiang Z; Yu Q
Life Sci; 2024 Jan; 337():122355. PubMed ID: 38104861
[TBL] [Abstract][Full Text] [Related]
14. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma.
Yu Z; Guo J; Liu Y; Wang M; Liu Z; Gao Y; Huang L
J Nanobiotechnology; 2022 Jan; 20(1):9. PubMed ID: 34983554
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of farnesoid X receptor agonists.
Ali AH; Carey EJ; Lindor KD
Ann Transl Med; 2015 Jan; 3(1):5. PubMed ID: 25705637
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid in primary biliary cholangitis: where we stand.
Manne V; Kowdley KV
Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
[TBL] [Abstract][Full Text] [Related]
20. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model.
Olthof PB; Huisman F; Schaap FG; van Lienden KP; Bennink RJ; van Golen RF; Heger M; Verheij J; Jansen PL; Olde Damink SW; van Gulik TM
Br J Surg; 2017 Apr; 104(5):590-599. PubMed ID: 28195307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
